Fig. 7: Artesunate suppresses BCR-ABL signaling transduction and enhances CML cell apoptosis with imatinib.
From: Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
A, B K562 and KBM5 cells were treated with ART for 24 h, followed by WB analysis with the specific antibodies. C K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by WB analysis with the specific antibodies. D K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by Annexin V-FITC/PI staining and flow cytometric analyses.
